Rationale and Design of Triple AXEL: Trial for Early Anticoagulation in Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation

Abstract

Rationale

Patients with atrial fibrillation (AF) in the acute stage of ischemic stroke or transient ischemic attack (TIA) are at high risk of recurrent stroke, but the optimal anticoagulation strategy remains unclear due to the concern of intracranial bleeding. Novel oral anticoagulants compared to warfarin might be more safe and efficacious in patients suitable for early anticoagulation.

Aims

This trial is to evaluate the feasibility of early anticoagulation with rivaroxaban in acute ischemic stroke or TIA patients with nonvalvular AF.

Design

This is a randomized, open-label, blinded endpoint evaluation trial. Inclusion criteria are (1) nonvalvular AF, (2) presumed cardioembolic stroke or transient ischemic attack (TIA) confirmed by MRI within five-days from onset, and (3) mild to moderate stroke severity. We will randomize 196 patients to either rivaroxaban (10 mg once daily for five-days followed by 15 mg or 20 mg once daily) or dose-adjusted warfarin (coadministration of aspirin 100 mg per day until achieving international normalized ratio of 1·7). The study is registered in ClinicalTrials.gov (NCT02042534).

Study outcomes

The primary endpoint is the composite of recurrent ischemic lesion and intracranial bleeding on MRI at four-weeks. Secondary endpoints are recurrent ischemic lesions, intracranial bleeding, major bleeding, major vascular events, four-week modified Rankin Scale score, and duration of hospitalization after randomization.

Discussion

The results of this proof-of-concept trial will guide go/no-go decision to a large phase 3 confirmatory trial.

Keywords

acute ischemic stroke atrial fibrillation NOAC rivaroxaban TIA warfarin

Get full access to this article

View all access options for this article.

References

Group EEAFTS. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342:1255–62.

Harrison

Johnston

Massicotte

Crowther

Moffat

Hirsh

. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133–6.

Crowther

Ginsberg

Kearon

. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159:46–8.

Freedman

. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992; 32:196–209.

Jauch

Saver

Adams

Jr . Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870–947.

Connolly

Ezekowitz

Yusuf

. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139–51.

Patel

Mahaffey

Garg

. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–91.

Granger

Alexander

McMurray

. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981–92.

Giugliano

Ruff

Braunwald

. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093–104.

10.

Bang

Hong

Heo

. New oral anticoagulants may be particularly useful for asian stroke patients. J Stroke 2014; 16:73–80.

11.

Schulman

Kearon

, SOCOAOTS, Standardization Committee Of The International Society On T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692–4.

12.

Saxena

Lewis

Berge

Sandercock

PAG

Koudstaal

, Group ftISTC. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the international stroke trial. Stroke 2001; 32:2333–7.

13.

Berge

Abdelnoor

Nakstad

Sandset

. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355:1205–10.

14.

Kang

Latour

Chalela

Dambrosia

Warach

. Early ischemic lesion recurrence within a week after acute ischemic stroke. Ann Neurol 2003; 54:66–74.

15.

Hylek

Phillips

. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 2001; 285:2370–5.

16.

Miyasaka

Barnes

Gersh

. Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 to 2000, and Implications on the projections for future prevalence. Circulation 2006; 114:119–25.

17.

Jung

Lee

Kim

. Secular trends in ischemic stroke characteristics in a rapidly developed country: results from the Korean Stroke Registry Study (secular trends in Korean stroke). Circ Cardiovasc Qual Outcomes 2012; 5:327–34.

18.

Kim

Han

Park

. Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry. Int J Stroke 2014; 9:514–8.

19.

Schwamm

Fonarow

Reeves

. Get with the guidelines–stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009; 119:107–15.

20.

Paciaroni

Agnelli

Micheli

Caso

. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38:423–30.

21.

Whiteley

Adams

Jr Bath

. Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet Neurol 2013; 12:539–45.

22.

Furie

Kasner

Adams

. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227–76.

23.

Furie

Goldstein

Albers

. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012; 43:3442–53.

24.

Patel

Hellkamp

Lokhnygina

. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013; 61:651–8.

25.

Azoulay

Dell'aniello

Simon

Renoux

Suissa

. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014; 35:1881–7.

26.

Wallentin

Yusuf

Ezekowitz

. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376:975–83.

27.

Piccini

Hellkamp

Lokhnygina

. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF Trial. J Am Heart Assoc 2014; 3:e000521.

28.

Mackman

. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108:1447–52.

29.

Ploen

Sun

Zhou

. Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke. J Cereb Blood Flow Metab 2014; 34:495–501.

30.

Shibazaki

Kimura

Aoki

Saji

Sakai

. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331:90–3.

31.

Huisman

Lip

Diener

Brueckmann

Van Ryn

Clemens

. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107:838–47.

32.

Camm

Lip

De Caterina

. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719–47.

33.

Culebras

Messe

Chaturvedi

Kase

Gronseth

. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82:716–24.

34.

Merino

Warach

. Imaging of acute stroke. Nat Rev Neurol 2010; 6:560–71.

35.

Group MSC. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data. Stroke 2006; 37:2521–5.

36.

Ebinger

Christensen

De Silva

. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke 2009; 40:1353–8.

37.

Coutts

Hill

Simon

Sohn

Scott

Demchuk

. Silent ischemia in minor stroke and TIA patients identified on MR imaging. Neurology 2005; 65:513–7.

38.

Kang

Latour

Chalela

Dambrosia

Warach

. Early and late recurrence of ischemic lesion on MRI: evidence for a prolonged stroke-prone state? Neurology 2004; 63:2261–5.

39.

Coutts

Simon

Eliasziw

. Triaging transient ischemic attack and minor stroke patients using acute magnetic resonance imaging. Ann Neurol 2005; 57:848–54.

40.

Kang

Lattimore

Latour

Warach

. SIlent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol 2006; 63:1730–3.

41.

Purroy

Montaner

Rovira

Delgado

Quintana

Álvarez-Sabín

. Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke 2004; 35:2313–9.